Last reviewed · How we verify
Urinary tract infection caused by Klebsiella
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Tobi · Novartis
- Maxipime · Baxter
Cefepime is a cephalosporin antibacterial drug. - Vabomere · Rempex Pharms Inc
Vabomere works by binding to and inhibiting bacterial beta-lactamase enzymes, allowing other antibiotics to effectively target and kill bacteria. - Maxipime · Baxter
Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis. - Cystadane · Recordati
- Pipracil
Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death. - Cefepim · University Hospital Tuebingen
- Ciprofloxacine · Poitiers University Hospital
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
- Zymar · Allergan
- Invanz · Merck & Co.
Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Arikayce Kit · Bristol-Myers Squibb
Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria. - Fortaz · Pai Holdings Pharm
Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death. - Recarbrio · Merck & Co.
Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria. - Fortaz · Pai Holdings Pharm
Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance. - Fetroja · Shionogi
Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death. - Noroxin
- Floxin
- Cipro · Bayer AG
- Cystadane · Mayo Clinic
- Ceftazidim · Tel-Aviv Sourasky Medical Center
- Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Urinary tract infection caused by Klebsiella patent landscape — cliff calendar, originator estates, attackable patents
- Urinary tract infection caused by Klebsiella treatment landscape brief
- Urinary tract infection caused by Klebsiella treatment updates RSS
Frequently asked questions about Urinary tract infection caused by Klebsiella
What drugs treat Urinary tract infection caused by Klebsiella?
Tracked treatments include Ramycin, Tobi, Maxipime, Vabomere, Cystadane, Pipracil, Cefepim, Ciprofloxacine.
What is the treatment for Urinary tract infection caused by Klebsiella?
Standard treatment for Urinary tract infection caused by Klebsiella includes Ramycin, Tobi, Maxipime, Vabomere, Cystadane. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Urinary tract infection caused by Klebsiella patent cliff · Urinary tract infection caused by Klebsiella CI report
- Treatment: Ramycin
- Treatment: Tobi · Novartis
- Treatment: Maxipime · Baxter
- Treatment: Vabomere · Rempex Pharms Inc
- Treatment: Maxipime · Baxter
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing